259 related articles for article (PubMed ID: 25482929)
21. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
[TBL] [Abstract][Full Text] [Related]
22. Cystic Pancreatic Neuroendocrine Tumors Represent a Distinct Clinical Entity with Less Aggressive Biological Behaviors.
Cheng Y; Wu D; Wang L; Liu H; Xiong Y; Xu J; Hu S; Zhan H
J Surg Res; 2021 Apr; 260():134-140. PubMed ID: 33340866
[TBL] [Abstract][Full Text] [Related]
23. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma.
Zurawel RH; Allen C; Chiappa S; Cato W; Biegel J; Cogen P; de Sauvage F; Raffel C
Genes Chromosomes Cancer; 2000 Jan; 27(1):44-51. PubMed ID: 10564585
[TBL] [Abstract][Full Text] [Related]
24. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors.
Komori Y; Yada K; Ohta M; Uchida H; Iwashita Y; Fukuzawa K; Kashima K; Yokoyama S; Inomata M; Kitano S
J Hepatobiliary Pancreat Sci; 2014 Apr; 21(4):288-95. PubMed ID: 24002888
[TBL] [Abstract][Full Text] [Related]
25. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total
Tirosh A; Papadakis GZ; Millo C; Sadowski SM; Herscovitch P; Pacak K; Marx SJ; Yang L; Nockel P; Shell J; Green P; Keutgen XM; Patel D; Nilubol N; Kebebew E
Eur J Endocrinol; 2017 May; 176(5):575-582. PubMed ID: 28289088
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.
Klieser E; Urbas R; Stättner S; Primavesi F; Jäger T; Dinnewitzer A; Mayr C; Kiesslich T; Holzmann K; Di Fazio P; Neureiter D; Swierczynski S
Hum Pathol; 2017 Jul; 65():41-52. PubMed ID: 28235630
[TBL] [Abstract][Full Text] [Related]
27. Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place.
de Mestier L; Gaujoux S; Cros J; Hentic O; Vullierme MP; Couvelard A; Cadiot G; Sauvanet A; Ruszniewski P; Richard S; Hammel P
Ann Surg; 2015 Aug; 262(2):384-8. PubMed ID: 25185468
[TBL] [Abstract][Full Text] [Related]
28. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of the expression of Hedgehog proteins in cervical carcinoma FIGO stages I-IV treated with radiotherapy or chemoradiotherapy.
Bohr Mordhorst L; Ahlin C; Sorbe B
Gynecol Oncol; 2014 Nov; 135(2):305-11. PubMed ID: 25158038
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of hedgehog pathway molecules and FOXM1 in non-small cell lung carcinomas.
Gialmanidis IP; Bravou V; Amanetopoulou SG; Varakis J; Kourea H; Papadaki H
Lung Cancer; 2009 Oct; 66(1):64-74. PubMed ID: 19200615
[TBL] [Abstract][Full Text] [Related]
31. Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors--diagnostic accuracy: NF-pNET and low tumor burden.
Jilesen AP; Busch OR; van Gulik TM; Gouma DJ; Nieveen van Dijkum EJ
Dig Surg; 2014; 31(6):407-14. PubMed ID: 25572908
[TBL] [Abstract][Full Text] [Related]
32. [Recent advances in treatment of pancreatic neuroendocrine tumors].
Imamura M
Nihon Geka Gakkai Zasshi; 2008 May; 109(3):143-6. PubMed ID: 18536317
[TBL] [Abstract][Full Text] [Related]
33. PTCH1 and SMO gene alterations in keratocystic odontogenic tumors.
Sun LS; Li XF; Li TJ
J Dent Res; 2008 Jun; 87(6):575-9. PubMed ID: 18502968
[TBL] [Abstract][Full Text] [Related]
34. Multifocality is not associated with worse survival in sporadic pancreatic neuroendocrine tumors.
Gudmundsdottir H; Graham RP; Sonbol MB; Smoot RL; Truty MJ; Kendrick ML; Nagorney DM; Habermann EB; Halfdanarson TR; Cleary SP
J Surg Oncol; 2021 Dec; 124(7):1077-1084. PubMed ID: 34310723
[TBL] [Abstract][Full Text] [Related]
35. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.
Saller J; Seydafkan S; Shahid M; Gadara M; Cives M; Eschrich SA; Boulware D; Strosberg JR; Aejaz N; Coppola D
Cancer Genomics Proteomics; 2019; 16(5):309-318. PubMed ID: 31467225
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic neuroendocrine tumors: contemporary diagnosis and management.
Parbhu SK; Adler DG
Hosp Pract (1995); 2016 Aug; 44(3):109-19. PubMed ID: 27404266
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes in MEN-1 patients with pancreatic neuroendocrine neoplasms: an Israeli specialist center experience.
Oleinikov K; Uri I; Jacob H; Epshtein J; Benson A; Ben-Haim S; Atlan K; Tal I; Meirovitz A; Maimon O; Lev-Cohain N; Mazeh H; Glaser B; Gross DJ; Grozinsky-Glasberg S
Endocrine; 2020 Apr; 68(1):222-229. PubMed ID: 32036501
[TBL] [Abstract][Full Text] [Related]
38. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.
Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM
BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors.
Song KB; Kim SC; Kim JH; Seo DW; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
Pancreas; 2016 Feb; 45(2):187-92. PubMed ID: 26474434
[TBL] [Abstract][Full Text] [Related]
40. Aberrant methylation of the PTCH1 gene promoter region in aberrant crypt foci.
Peng L; Hu J; Li S; Wang Z; Xia B; Jiang B; Li B; Zhang Y; Wang J; Wang X
Int J Cancer; 2013 Jan; 132(2):E18-25. PubMed ID: 22945423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
